Citius Pharmaceuticals to Present at NobleCon15 Investor Conference

Friday, January 25, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

CRANFORD, N.J., Jan. 25, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (CTXR), a specialty pharmaceutical

company focused on adjunctive cancer care and critical care drug products, announced today that its Vice President of Corporate Development, Andrew Scott, will present at NobleConXV - Noble Capital Markets' Fifteenth Annual
Investor Conference at the W Hotel, Fort Lauderdale, Florida on Monday, January 28th at 10:00am Eastern Standard Time in Studio 2.

During the conference, Mr. Scott will deliver the Company's corporate presentation and discuss business operations and updates. Citius recently signed a license agreement with MD Anderson Cancer Center to develop and commercialize a novel approach to reducing post-operative infections associated with surgical implants. The initial product called "Mino-Wrap", or CITI 101, is a liquefying gel-based wrap containing minocycline and rifampin for reducing tissue expander (TE) infections following breast reconstructive surgeries.

Citius Pharmaceuticals, Inc. will also be available for one-on-one meetings. To arrange a meeting with the company, please contact Mr. Andrew Scott: ascott@citiuspharma.com.

About Citius Pharmaceuticals, Inc.

Citius is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives, cancer care and unique prescription products that use innovative, patented or proprietary formulations of previously approved active pharmaceutical ingredients. We seek to achieve leading market positions by providing therapeutic products that address unmet medical needs. By using previously approved drugs with substantial safety and efficacy data, we seek to reduce the risks associated with pharmaceutical product development and regulatory requirements. Citius develops products that have intellectual property protection and competitive advantages to existing therapeutic approaches. For more information, please visit www.citiuspharma.com.

Contact:

Andrew Scott                                                               Vice President, Corporate Development                                                        (o) 908-967-6677 ascott@citiuspharma.com 

Cision View original content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-noblecon15-investor-conference-300783963.html

SOURCE Citius Pharmaceuticals, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store